论文部分内容阅读
目前的心力衰竭(简称心衰)治疗指南将慢性收缩性心衰分为A、B、C、D4个阶段,并将每个阶段与其对应的治疗方案相联系。统计表明,B阶段的心衰患者数量是C、D阶段患者数量总和的4倍,处在B阶段的患者将逐步进展为有症状的心衰。研究发现在高危人群中测定血浆脑钠素水平,然后在高脑钠素水平的人群中行心脏彩色超声心动图检查是筛选B阶段心衰的经济有效的方法。血管紧张素转换酶抑制剂/受体阻滞剂、β受体阻滞剂可以改善B阶段心衰患者的预后,醛固酮受体拮抗剂、地高辛在慢性心衰B阶段中的应用并未发现有力的证据,而作为非药物治疗的埋藏式心脏转复除颤器或心脏再同步化治疗在该阶段治疗中的作用仍需进一步研究证实。
The current guidelines for the treatment of heart failure (referred to as heart failure) will be divided into chronic systolic heart failure A, B, C, D 4 stages, and each stage associated with the corresponding treatment programs. Statistics show that the number of patients with heart failure in stage B is 4 times the total number of patients in stage C and stage D. Patients in stage B will progress to symptomatic heart failure. The study found that determining plasma brain natriuretic peptide levels in high-risk populations and then performing cardiac color echocardiography in patients with elevated brain natriuretic peptide is a cost-effective method for screening for B-stage heart failure. Angiotensin converting enzyme inhibitors / blockers, beta blockers can improve the prognosis of patients with stage B heart failure, aldosterone receptor antagonist, digoxin in chronic heart failure stage B application has not Found strong evidence, and as a non-drug-treated implantable cardioverter defibrillator or cardiac resynchronization therapy in this phase of treatment still need further study confirmed.